How have the shares performed?
Maravai LifeSciences Holdings Inc. (MRVI) saw an uptrend of 0.62% in the recent trading with $42.00 being its most recent. The current price level -3.93% lower than the highest price of $43.72 marked by the stock while trading over the past 52-weeks, whereas it is 77.82% higher than the lowest price of $23.62 the company dropped to over past 52-weeks. The latest news story on MRVI appeared in GlobeNewswire under the title “Maravai LifeSciences Announces June 2021 Investor Conference Schedule” on May-26-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -3.93% below one month high and is +25.26% above of the lowest during that time. Looking into the simple moving average, Maravai LifeSciences Holdings Inc. (MRVI)’s stock stands at a SMA-50 of $37.10 while that of 5-day is reading $41.66.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
Maravai LifeSciences Holdings Inc. Earnings – What Happened With MRVI
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Maravai LifeSciences Holdings Inc. (MRVI) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of 30.00% for net revenue. During the reported three-month period, company’s sales were $148.21 billion while analysts on average were estimating the same to be $192.29 million.
MRVI – Maravai LifeSciences Holdings Inc. Stock Earnings Estimates
The perspective of Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)’s current quarter earnings identifies that analysts are in consensus over the estimate of 0.2 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was 0.26.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 96.65 million. MRVI does have institutional investors; and they hold 88.30% of the stock.
Maravai LifeSciences Holdings Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, MRVI declared 20,700,000 shares have been sold in 4 insider transactions over the past three months.
As on Mar 30, 2021, GTCR, LLC was the top most holder in Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) with an ownership of 27.65 million shares of the company or 24.18% of the stake worth $985.32 million. The filing also reveals FMR, LLC as the second largest holder in the company with a control over 8.49% of the outstanding shares. Its stake is worth $345.82 million for having 9.7 million shares in hand.
Massachusetts Financial Services Co. also came holding a key position in the company during the recent quarter and it now holds 4.71% of the outstanding shares. With this there are now 205 institutions which have possession in MRVI’s shares.
Currently, the stock has been recommended as Strong Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Maravai LifeSciences Holdings Inc. was 2.54 while posting a debt to equity ratio of 5.24. The count was 660.69 for long-term debt to equity ratio.